DE60214830D1 - C2,8-disubstituierte adenosinderivate und ihre verschiedenen verwendungen - Google Patents

C2,8-disubstituierte adenosinderivate und ihre verschiedenen verwendungen

Info

Publication number
DE60214830D1
DE60214830D1 DE60214830T DE60214830T DE60214830D1 DE 60214830 D1 DE60214830 D1 DE 60214830D1 DE 60214830 T DE60214830 T DE 60214830T DE 60214830 T DE60214830 T DE 60214830T DE 60214830 D1 DE60214830 D1 DE 60214830D1
Authority
DE
Germany
Prior art keywords
adenosine derivatives
various uses
disubstituted
compounds
disubstituted adenosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60214830T
Other languages
German (de)
English (en)
Inventor
Tilburg Erica Van
Ad Ijzerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Can Fite Biopharma Ltd
Universiteit Leiden
Original Assignee
Can Fite Biopharma Ltd
Universiteit Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd, Universiteit Leiden filed Critical Can Fite Biopharma Ltd
Application granted granted Critical
Publication of DE60214830D1 publication Critical patent/DE60214830D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE60214830T 2001-03-03 2002-03-03 C2,8-disubstituierte adenosinderivate und ihre verschiedenen verwendungen Expired - Lifetime DE60214830D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0105335A GB2372741A (en) 2001-03-03 2001-03-03 C2,8-Disubstituted adenosine derivatives and their different uses
PCT/IL2002/000161 WO2002070534A1 (en) 2001-03-03 2002-03-03 C2, 8-disubstituted adenosine derivatives and their different uses

Publications (1)

Publication Number Publication Date
DE60214830D1 true DE60214830D1 (de) 2006-11-02

Family

ID=9909950

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60214830T Expired - Lifetime DE60214830D1 (de) 2001-03-03 2002-03-03 C2,8-disubstituierte adenosinderivate und ihre verschiedenen verwendungen

Country Status (7)

Country Link
US (1) US7112574B2 (cg-RX-API-DMAC7.html)
EP (1) EP1368364B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004522795A (cg-RX-API-DMAC7.html)
AT (1) ATE340185T1 (cg-RX-API-DMAC7.html)
DE (1) DE60214830D1 (cg-RX-API-DMAC7.html)
GB (1) GB2372741A (cg-RX-API-DMAC7.html)
WO (1) WO2002070534A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE532791T1 (de) * 2004-09-17 2011-11-15 Kissei Pharmaceutical In der 8-stellung modifiziertes purin- nukleosidderivat und dessen medizinische verwendung
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
EP2010553A1 (en) * 2006-04-03 2009-01-07 AstraZeneca AB Substituted adenines and the uses thereof
EP2013211B1 (en) 2006-04-21 2012-03-14 Novartis AG Purine derivatives for use as adenosin a2a receptor agonists
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
CN108129535A (zh) * 2017-12-19 2018-06-08 兰州奥凯化工公司 8-溴腺苷的合成方法
KR102550983B1 (ko) * 2021-03-26 2023-07-07 퓨쳐메디신 주식회사 A2a 및 a3 아데노신 수용체에 길항작용을 하는 아데노신 유도체 및 이의 제조방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3968102A (en) * 1974-04-18 1976-07-06 Kohjin Co., Ltd. S-substituted-2-thioadenosines
US3966102A (en) * 1974-08-08 1976-06-29 Standard Oil Company Single unit carrier for drinkware
US5189027A (en) * 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
US5278150A (en) * 1992-04-24 1994-01-11 Whitby Research, Inc. 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
US6514949B1 (en) * 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6448235B1 (en) * 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US5998423A (en) * 1996-10-08 1999-12-07 Therasys, Inc. Methods for modulating melanin production
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
WO2000072799A2 (en) * 1999-05-27 2000-12-07 The University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US6180615B1 (en) * 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
AU4138601A (en) * 1999-12-03 2001-06-12 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives

Also Published As

Publication number Publication date
GB0105335D0 (en) 2001-04-18
JP2004522795A (ja) 2004-07-29
US20040116374A1 (en) 2004-06-17
US7112574B2 (en) 2006-09-26
WO2002070534A1 (en) 2002-09-12
EP1368364B1 (en) 2006-09-20
EP1368364A1 (en) 2003-12-10
GB2372741A (en) 2002-09-04
ATE340185T1 (de) 2006-10-15

Similar Documents

Publication Publication Date Title
EE200300324A (et) Asendatud alküülamiini derivaadid ja nende kasutamismeetodid
AR022469A1 (es) Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevas sustancias
DE60118003D1 (de) Harnstoffderivate und ihre verwendung
CA2534570A1 (en) Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
BRPI0408681A (pt) compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
BRPI0515030A (pt) derivados de purina como agonistas de receptor de adenosina a3 e a1
BRPI0510762A (pt) derivados de tetraidronaftiridina úteis como ligantes do receptor de histamina h3
MXPA03009439A (es) Derivados de 4,5-dihidro-1h-pirazol que tienen una potente actividad antagonistica de cb1.
WO2004078110A3 (en) Fused imizadoles as transforming growth factor (tgf) inhibitors
DE602004015810D1 (de) Substituierte isochinolinderivate und anwendungsverfahren
FR2822826B1 (fr) Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MXPA04002583A (es) Derivados de 4,5-dihidro-1h-pirazol novedosos que tienen actividad antagonistica del canabinoide (cb1).
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
WO2003024928A3 (en) Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
EA200601065A1 (ru) Производные имидазола, способы их получения и применения
DE60214830D1 (de) C2,8-disubstituierte adenosinderivate und ihre verschiedenen verwendungen
WO2005080345A3 (en) Imidazoline derivatives having cb1-antagonistic activity
NO20010940L (no) TAN-1057 derivater
BG102707A (bg) Нови триазолопурини, метод за тяхното получаване и тяхното приложение като лекарствени средства
NO20052172D0 (no) 4-aminopiperidinderivater, fremgangsmate for deres fremstilling og deres anvendelse som medikamenter
UA95780C2 (en) Xanthine derivatives as selective hm74a agonists
WO2003039482A3 (en) Polymorphs of fexofenadine base
PE20030125A1 (es) PIRIDO[1,2-c]PIRIMIDINA COMO AGENTES ANTIBACTERIANOS

Legal Events

Date Code Title Description
8332 No legal effect for de